2000 Sierra Point Parkway
Suite 400
Brisbane, CA 94005
United States
415 798 8589
https://www.tempesttx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 17
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Stephen R. Brady J.D., LLM | CEO, President & Director | 923.24k | N/A | 1970 |
Mr. Nicholas Maestas | VP of Strategy & Finance and Secretary | 465.43k | N/A | 1981 |
Dr. Samuel Whiting M.D., Ph.D. | Executive VP & Chief Medical Officer | 667.65k | N/A | 1966 |
Mr. Justin Trojanowski | Corporate Controller, Treasurer & Principal Accounting Officer | N/A | N/A | 1988 |
Ms. Lindsay Young | Head of Human Resources | N/A | N/A | N/A |
Dr. Sharon Sakai Ph.D., RAC | Head of Regulatory & Quality | N/A | N/A | N/A |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Tempest Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.